Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eziafa I Oduah

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cancer Biology & Therapy|February 12, 2020
Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?Eziafa I Oduah, Steven R Grossman
Journal of Thoracic Disease|July 11, 2022
The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma-successes and challengesEziafa I Oduah, Chung-Shien Lee, Nagarashee Seetharamu
Pharmaceuticals (Basel, Switzerland)|July 8, 2016
Heparin: Past, Present, and FutureEziafa I Oduah, Robert J Linhardt, Susan T Sharfstein
Frontiers in Oncology|April 25, 2024
Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implicationsEziafa I Oduah, Susan T Sharfstein, Nagashree Seetharamu, et al.
Cancers|June 13, 2025
A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLCKimberly Burcher, Pooja Karukonda, Christopher Kelsey, et al.
Future Oncology (London, England)|November 27, 2024
Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancerJordyn P Higgins, Jennifer W Carlisle, Nader H Moniri, et al.
Cancers|July 12, 2025
Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future PerspectivesDiamone Gathers, Cameron Oswalt, Laura Alder, et al.
Future Oncology (London, England)|April 6, 2026
Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II studyEziafa I Oduah, Tian Zhang, Sin-Ho Jung, et al.
Journal for Immunotherapy of Cancer|November 1, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulationJingxuan Zhang, Lin Lin, Jennifer H Enzor, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysisCameron Wood, Liliana Lyniv, James M Isaacs, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancer Biology & Therapy|February 12, 2020
Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?Eziafa I Oduah, Steven R Grossman
Journal of Thoracic Disease|July 11, 2022
The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma-successes and challengesEziafa I Oduah, Chung-Shien Lee, Nagarashee Seetharamu
Pharmaceuticals (Basel, Switzerland)|July 8, 2016
Heparin: Past, Present, and FutureEziafa I Oduah, Robert J Linhardt, Susan T Sharfstein
Frontiers in Oncology|April 25, 2024
Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implicationsEziafa I Oduah, Susan T Sharfstein, Nagashree Seetharamu, et al.
Cancers|June 13, 2025
A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLCKimberly Burcher, Pooja Karukonda, Christopher Kelsey, et al.
Future Oncology (London, England)|November 27, 2024
Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancerJordyn P Higgins, Jennifer W Carlisle, Nader H Moniri, et al.
Cancers|July 12, 2025
Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future PerspectivesDiamone Gathers, Cameron Oswalt, Laura Alder, et al.
Future Oncology (London, England)|April 6, 2026
Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II studyEziafa I Oduah, Tian Zhang, Sin-Ho Jung, et al.
Journal for Immunotherapy of Cancer|November 1, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulationJingxuan Zhang, Lin Lin, Jennifer H Enzor, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysisCameron Wood, Liliana Lyniv, James M Isaacs, et al.
Pageof 1